IQVIA Holdings, Inc.
217.83-0.30 (-0.14%)
Oct 29, 4:00:02 PM EDT · NYSE · IQV · USD
Key Stats
Market Cap
37.10BP/E (TTM)
29.92Basic EPS (TTM)
7.28Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
IQVIA CFO transition announced
IQVIA announced on September 2, 2025, that Michael J. Fedock will step up as Executive Vice President and CFO effective February 28, 2026, succeeding Ronald E. Bruehlman, who retires to Senior Advisor to the CEO for a smooth handover. Fedock, with over 25 years in healthcare and key internal roles since 2016, brings deep expertise to steer finance amid growth. His base salary rises to $750,000, with 100% incentive target. This planned shift bolsters continuity while honoring Bruehlman's pivotal tenure through IPOs and mergers.
10-Q
Q2 FY2025 results
IQVIA's Q2 revenues climbed 5.3% year-over-year to $4,017 million, fueled by 8.9% growth in Technology & Analytics Solutions while Research & Development Solutions edged up 2.5% amid fading COVID work; yet operating income dipped 2.7% to $506 million as costs rose faster, squeezing margins to 12.6%. Diluted EPS fell to $1.54 from $1.97, consistent with 173.2 million shares. Cash swelled to $2,039 million, with operating cash flow at $1,011 million for the half-year, but free cash flow (derived) of $718 million trailed last year's $822 million after $293 million capex. Debt hit $15,573 million following a $2,000 million notes issuance in June 2025, offset by $1,032 million in share repurchases. Immaterial acquisitions added $236 million goodwill. Veeva litigation drags on, risking IP claims.
8-K
IQVIA Q2 revenue up 5.3%
IQVIA Holdings reported Q2 2025 revenue of $4,017 million, up 5.3% year-over-year, driven by TAS segment growth of 8.9% while R&DS rose 2.5%. Adjusted EBITDA hit $910 million, with net bookings at $2.5 billion yielding a 1.12x book-to-bill ratio and backlog expanding to $32.1 billion. The company repurchased $607 million in shares. Full-year guidance now projects revenue of $16.1-16.3 billion, yet COVID revenue step-downs loom.
IPO
Website
Employees
Sector
Industry
CRL
Charles River Laboratories Inte
180.15-7.78
DGX
Quest Diagnostics Incorporated
174.78-3.50
DHR
Danaher Corporation
214.01-2.89
ICLR
ICON plc
165.95-11.78
ILMN
Illumina, Inc.
95.03-2.77
LH
Labcorp Holdings Inc.
248.14-11.55
MEDP
Medpace Holdings, Inc.
584.57+4.04
NOTV
Inotiv, Inc.
1.33-0.01
QGEN
Qiagen N.V.
47.19-0.76
TMO
Thermo Fisher Scientific Inc
558.31+0.68